Abstract

Diabetic cardiomyopathy (DCM) is a common complication of diabetes mellitus (DM), resulting in high mortality. Myocardial fibrosis, cardiomyocyte apoptosis and inflammatory cell infiltration are hallmarks of DCM, leading to cardiac dysfunction. To date, few effective approaches have been developed for the intervention of DCM. In the present study, we investigate the effect of krill oil (KO) on the prevention of DCM using a mouse model of DM induced by streptozotocin and a high-fat diet. The diabetic mice developed pathological features, including cardiac fibrosis, apoptosis and inflammatory cell infiltration, the effects of which were remarkably prevented by KO. Mechanistically, KO reversed the DM-induced cardiac expression of profibrotic and proinflammatory genes and attenuated DM-enhanced cardiac oxidative stress. Notably, KO exhibited a potent inhibitory effect on NLR family pyrin domain containing 3 (NLRP3) inflammasome that plays an important role in DCM. Further investigation showed that KO significantly upregulated the expression of Sirtuin 3 (SIRT3) and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), which are negative regulators of NLRP3. The present study reports for the first time the preventive effect of KO on the pathological injuries of DCM, providing SIRT3, PGC-1α and NLRP3 as molecular targets of KO. This work suggests that KO supplementation may be a viable approach in clinical prevention of DCM.

Highlights

  • The prevalence of diabetes mellitus (DM) is increasing dramatically worldwide

  • In the present study, we report the preventive effect of krill oil (KO) on the pathological injuries of Diabetic cardiomyopathy (DCM) using a mouse model of T2DM

  • The present study found that KO upregulated the protein levels Sirtuin 3 (SIRT3) and PGC-1α (Figure 6), the effects of which were in accordance with KO’s inhibitory effect on NLR family pyrin domain containing 3 (NLRP3)

Read more

Summary

Introduction

The prevalence of diabetes mellitus (DM) is increasing dramatically worldwide. The global DM prevalence is estimated to be 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [1]. Diabetic cardiomyopathy (DCM) is a common complication of DM, exhibiting pathophysiological abnormalities, including inflammation, oxidative/nitrosative stress, cardiomyocyte apoptosis and accumulation of fibrosis in the heart [2]. DCM results in heart failure [3]. The current strategies to prevent DCM are far from satisfactory. It is important to develop more effective approaches for the prevention of DCM

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call